ArticleTranslational cancer research2023

Efficacy, safety and pharmacokinetics of apatinib plus etoposide versus apatinib alone for platinum-resistant recurrent ovarian cancer: protocol of a multicenter, open-label, randomized phase 2 trial.

Zhiguo Hou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.